WTO members affirmed that the TRIPS Agreement should be interpreted and implemented in a manner supportive of WTO members' right to protect public health and, in particular, to promote access to medicines for all and that TRIPS should not prevent members from taking measures to protect public health.
No numerical targets were set.
Compulsory licences and Government-use orders to manufacture, import or otherwise deal with patent-protected medicines are among the key TRIPS public health flexibilities that have already been used for domestic production or importation of medicines by many developing-country Governments to reduce the cost of medicines. For more information and some recent examples of compulsory licensing and Government-use licences for essential medicines, including ARVs, can be found in the MDG Gap Task Force Report 2011, page 58.
No numerical target was set, thus it is difficult to measure a gap.
The Doha Declaration on the TRIPS Agreement and Public Health builds on the WTO Agreement on TRIPS adopted in 1994.